Predictors of Arterio-Venous Fistula Failure: A post-hoc analysis of the FAVOURED Study

Yong Pey See1,3, Yeoungjee Cho1,2,11, Elaine M Pascoe2,11, Alan Cass4, Ashley Irish5,6, David Voss7, Kevan R Polkinghorne8, Lai Seong Hooi9, Loke-Meng Ong10, Peta-Anne Paul-Brent2,11, Peter G Kerr9, Trevor A Mori6, Carmel M Hawley1,2,11, David W Johnson1,2,11, and Andrea K Viecelli1,2,11, on Behalf of the Omega 3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Group*

1Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia; 2Australasian Kidney Trial Network, School of Medicine, University of Queensland, Brisbane, Australia; 3Department of Renal Medicine, Tan Tock Seng Hospital, Singapore; 4Menzies School of Health Research, Charles Darwin University, Darwin, Australia; 5Department of Nephrology, Fiona Stanley Hospital, Perth, Australia; 6Medical School, University of Western Australia, Perth, Australia; 7Middlemore Renal Department, Counties-Manukau Health, Auckland, New Zealand; 8Department of Nephrology, Monash Medical Centre, Melbourne, Australia; 9Department of Medicine and Hemodialysis Unit, Hospital Sultanah Aminah, Johor Bahru, Malaysia; 10Department of Nephrology, Penang Hospital, Georgetown, Malaysia; 11Translational Research Institute, Brisbane, Australia;

Corresponding author:
Dr Andrea Viecelli, MD, FRACP, PhD
Department of Nephrology
Princess Alexandra Hospital
Level 2, ARTS Building
199 Ipswich Road, Woolloongabba, QLD 4102, Australia
Phone: +61 7 3176 5080
Fax: +61 7 3176 5480
Email: andrea.viecelli@health.qld.gov.au
ABSTRACT

Background

An autologous arteriovenous fistula (AVF) is the preferred hemodialysis vascular access but successful creation is hampered by high rates of AVF failure. This study aimed to evaluate patient and surgical factors associated with AVF failure to improve vascular access selection and outcomes.

Methods

This is a post-hoc analysis of all participants of FAVOURED, a multi-center, double-blind, multinational, randomized placebo-controlled trial evaluating the effect of fish oil and/or aspirin in preventing AVF failure in patients receiving hemodialysis. The primary outcome of AVF failure was a composite of fistula thrombosis and/or abandonment and/or cannulation failure at 12 months post AVF creation and secondary outcomes included individual outcome components. Patient data (demographics, comorbidities, medications and laboratory data) and surgical factors (surgical expertise, anesthetic, intraoperative heparin use) were examined using multivariable logistic regression analyzes to evaluate associations with AVF failure.

Results

Of 536 participants, 253 patients (47%) experienced AVF failure during the study period. The mean age was 55 ± 14.4 years, 64% were male, 45% were diabetic and 4% had peripheral vascular disease. Factors associated with AVF failure included female sex (odds ratio [OR] 1.79, 95% confidence interval [CI] 1.20-2.68), lower diastolic blood pressure (OR for higher DBP 0.85, 95% CI 0.74-0.99), presence of central venous catheter (OR 1.49, 95% CI 1.02-2.20, p=0.04) and aspirin requirement (OR 1.60, 95% CI 1.00-2.56).

Conclusions
Female sex, requirement for aspirin therapy, requiring hemodialysis via a central venous catheter and lower diastolic blood pressure were factors associated with higher odds of AVF failure. These associations have potential implications for vascular access planning and warrant further studies.
INTRODUCTION

An autologous arteriovenous fistula (AVF) is the vascular access of choice for most patients requiring hemodialysis due to improved longevity once successfully established, lower associated mortality and lower health costs compared to an arteriovenous graft or central venous catheter. These long-term benefits are however hampered by exceedingly high rates of early AVF failure due to thrombosis and maturation failure affecting up to 60% of patients. It is thus not surprising that vascular access function is one of the most critically important outcomes for patients on hemodialysis and their caregivers.

Previous studies have identified delayed nephrology care, smaller arterial and venous calibre on sonographic evaluation and demographic factors such as older age and female sex to be associated with AVF failure while greater surgical experience and use of regional anesthesia were associated with better AVF outcomes. Unfortunately, many of these studies have shown inconsistent and conflicting outcomes likely driven by differences in study populations, sample size and methodology as well as substantial heterogeneity of outcome definitions. Scoring systems incorporating multiple factors have been used to improve predictive scoring for AVF failure; although showing promise they have not been shown to consistently predict vascular access outcomes when applied to different study populations. Furthermore, few studies have evaluated potentially modifiable predictors such as surgical expertise or anesthetic technique in different study populations including Australian and New Zealand cohorts.

This post-hoc analysis of the randomized controlled FAVOURED study conducted in Australia, New Zealand, Malaysia and United Kingdom was therefore performed to identify
potentially modifiable pre- and perioperative patient and surgical factors associated with AVF failure, defined as a clinically relevant composite outcome of thrombosis, abandonment and/or failure to cannulate within one year of AVF creation in patients requiring hemodialysis.

METHODS

The FAVOURED trial was a multicenter, double-blind randomized, placebo-controlled trial conducted in 35 hemodialysis centers in Australia, New Zealand, Malaysia and United Kingdom investigating the effect of fish oil supplementation or aspirin on preventing AVF failure amongst patients recruited between August 2008 and February 2014. The trial was registered with the Australia and New Zealand Clinical Trial Registry (ACTRN12607000569404). The original 2 by 2 factorial design was amended in June 2011 to allow patients who required ongoing aspirin therapy to be randomized to fish oil or matching placebo but continue open-label aspirin use when deemed medically required30. The FAVOURED trial had obtained local Human Research Ethics Committees in all participating centres prior to trial commencement.

Adult patients aged ≥ 19 years with stage 4 or 5 chronic kidney disease receiving or expected to receive hemodialysis within 12 months and scheduled for AVF creation were eligible for the study. Patients with significant bleeding risk or contraindication to use of the study agents were excluded. A detailed description of the study protocol has been published previously31.
Patient-related factors collected at baseline prior to AVF creation included demographic data (i.e. sex, age, region of recruitment [Australia, New Zealand and UK collectively referred as ANZ versus Malaysia]), clinical information (i.e. body mass index [BMI], waist-hip ratio, baseline blood pressure [BP] taken as per local practices, smoking history, cause of end-stage kidney disease [ESKD], presence of diabetes mellitus [DM], hypertension, peripheral vascular disease [PVD], ischemic heart disease [IHD], cerebrovascular disease status, presence of central venous catheter [CVC] and medications such as statins, erythropoiesis stimulating agents [ESA], calcium channel blockers [CCB], beta-blockers, aspirin and fish oil) and relevant blood investigations (i.e. full blood count [FBC], coagulation profile [INR, APTT], serum calcium, phosphate, parathyroid hormone [PTH], low density lipoprotein cholesterol [LDL-C] and glycated haemoglobin [HbA1c]) at the time of AVF creation.

Recorded surgical factors included the type of anesthesia used (i.e. general, regional or local), intra-operative heparin use, surgical expertise defined by level of training (i.e. trainee such as resident and registrar versus consultant) and type of AVF created (i.e. radiocephalic [RC], brachiocephalic [BC], brachiobasilic [BB] and others).

The primary outcome of AVF failure was a composite of fistula thrombosis and/or abandonment and/or cannulation failure at 12 months. Thrombosis was defined as the absence of a thrill or bruit by clinical examination and/or requirement of rescue intervention (medical thrombolysis or surgical thrombectomy). Abandonment was defined as permanent abandonment of the study AVF including unsalvageable thrombosis of the study AVF, imaging showing that the study AVF was unusable or not amenable to any intervention for its improvement, insertion of another dialysis access (new AVF, AVG, CVC or peritoneal dialysis access) or ligation of the study AVF. Cannulation failure was defined as failure to
successfully cannulate the study AVF during 8 or more of 12 consecutive hemodialysis sessions during the cannulation assessment period (Table S1).

STATISTICAL ANALYSIS

Baseline characteristics are presented as frequency (percentage), mean (± standard deviation) or median (interquartile range), as appropriate. Differences between patients with and without AVF failure were analyzed using the independent Student t-test or Mann-Whitney U test for continuous variables according to data distribution. χ² test and Fisher’s exact test were performed for categorical variables, as appropriate.

Associations between factors and the composite outcome of AVF failure were examined by univariable and multivariable logistic regression. All patient factors that were found to be associated with AVF failure on univariable logistic regression with p-values<0.2 were included in a multivariable logistic regression in Model 1. Diabetes mellitus was pre-specified for inclusion in Model 1 due to its clinical importance regardless of p-value on univariable logistic regression32. Similarly, the use of study agents (open-label aspirin, randomized aspirin or matching placebo and fish oil or matching placebo) was included in Model 1 as these agents were randomized interventions from the original FAVOURED trial. Surgical factors associated with AVF failure on univariable analysis (p<0.2) or pre-specified for inclusion due to its clinical importance (i.e. type of anesthesia, surgical expertise)25 were then included to patient factors in Model 1 to derive Model 2. Factors with more than 5% missing data were excluded from multivariable logistic regression. On preliminary analysis, sex-specific differences in diastolic BP (DBP) and site of AVF created were observed and therefore interactions between DBP and gender as well as site of AVF and gender on AVF...
failures were examined. Model fit was evaluated using the Hosmer-Lemeshow test and diagnostic accuracy was tested by the area under the operating characteristic curve (AUC). Subsequently, Model 2 was applied to determine factors associated with individual cause specific components of AVF failure (i.e. AVF thrombosis, abandonment and failure to cannulate at 12 months). P values <0.05 were considered statistically significant. Statistical analyzes were performed with Stata version 14.1 (Stata Corporation, College Station, Texas, USA).

RESULTS

Study participants

All 536 participants randomized and analyzed in the original FAVOURED study were included in this present study. Amongst those recruited, 334 participants were enrolled from Australia (62%), 144 from Malaysia (27%), 49 from New Zealand (9%), and 9 from United Kingdom (2%). The baseline characteristics for participants with and without AVF failure are shown in Table 1. More than 5% missing data were present for laboratory parameters including HbA1c, LDL-C, INR, APTT and PTH levels.

Predictors of AVF failure

AVF failure occurred in 253 participants (47%); 109 participants experienced at least one episode of AVF thrombosis, 121 participants had AVF abandonment and 212 participants experienced cannulation failure. On univariable logistic regression, female sex, older age, non-Malaysian region of recruitment, absence of hypertension, lower DBP and mean arterial pressure, higher parathyroid hormone level and open labelled (i.e. medically required) aspirin use were statistically significantly associated with increased odds of AVF failure (Table 2). Surgical expertise, type of anesthesia used, intra-operative anticoagulation use or the type of AVF created were not associated with AVF failure on univariable logistic regression.
Multivariable logistic regression of patient factors including female sex, age, region of recruitment, DBP, presence of DM, presence of PVD, presence of CVC, hemoglobin levels, use of CCB, randomization to aspirin and fish oil, was performed in Model 1. Diastolic blood pressure was chosen over history of hypertension and mean arterial pressure for inclusion into Model 1 as it is biologically plausible and most strongly associated statistically on univariable logistic regression. Female sex (adjusted OR 1.60, 95% CI 1.10-2.32), presence of CVC (adjusted OR 1.53, 95% CI 1.05-2.23) and open labelled aspirin use (adjusted OR 1.59, 95% CI 1.00-2.53) were associated with increased odds of AVF failure (Table 2). In contrast, every 10mmHg increase in DBP (adjusted OR 0.84, 95% CI 0.73-0.97) and Malaysian region of recruitment (adjusted OR 0.60, 95% CI 0.38-0.95 compared to ANZ) were associated with lower odds of AVF failure (Table 2).

When surgical factors (surgical expertise, type of AVF created and use of local versus general or regional anesthesia were added (Model 2), Malaysian region of recruitment was no longer associated with lower AVF failure (adjusted OR 0.66, 95% CI 0.34-1.25). Female sex (adjusted OR 1.79, 95% CI 1.20-2.68), DBP (adjusted OR 0.85, 95% CI 0.74-0.99), presence of CVC (adjusted OR 1.49, 95% CI 1.02-2.20) and open labelled use of aspirin (adjusted OR 1.60, 95% CI 1.00-2.56) remained associated with AVF failure. None of the other surgical factors were associated with AVF failure in Model 2. The Hosmer-Lemeshow goodness of fit were 6 (p=0.65) and 8.26(p=0.41) for Model 1 and 2 respectively. Furthermore, the addition of surgical factors did not improve the prediction of AVF failure (AUC 0.67 compared to 0.65 for Model 1, p=0.08).
Amongst the factors identified to be associated with AVF failure, diastolic blood pressure was potentially modifiable. An inverse relationship was observed between DBP and AVF failure that remained unchanged on multivariable analysis when factors used in Model 2 were added (Figure 1). The probability of AVF failure was greater than 50% with diastolic pressure of 80 mmHg and lower (Figure 1). There was similar trend towards greater probability of AVF failure with decreasing mean arterial pressure (Figure S1) and to a lesser extent with systolic BP (Figure S2). On the other hand, an association between higher pulse pressure and higher probability of AVF failure was observed (Figure S3).

Female participants had on average lower DBP (79.6 ± 13.0 mmHg) at baseline compared to males (82.4 ±13.5 mmHg, p=0.02) (Table S2), but no significant interaction between blood pressure and sex was observed (p=0.79). It was also noted that female patients had more upper arm AVFs created (62%) compared to only 29% (Table S3) in males but no significant interaction between AVF site and sex was observed (OR 1.20, 0.57-2.55 p=0.10).

**Predictors of the individual components of AVF failure**

The factors associated with the individual outcomes of AVF thrombosis, abandonment and cannulation failure were different (Table 3). Female sex was associated with increased odds of AVF abandonment (adjusted OR 2.02, 95% CI 1.27-3.20) and cannulation failure (adjusted OR 1.74, 95% CI 1.16-2.61) but not AVF thrombosis. The presence of PVD was associated with increased odds of AVF abandonment (adjusted OR 3.24, 95% CI 1.31-7.98). The presence of CVC, lower DBP and non-Malaysian region of recruitment were associated with higher odds of cannulation failure (adjusted OR [CVC] 1.66, 95% CI 1.11-2.46, [DBP] 0.80, 95% CI 0.68-0.93, [Region of recruitment] 0.50 95% CI 0.26-0.98, respectively). BC-
AVF were less likely to be abandoned compared to RC AVF (adjusted OR 0.48, 95% CI 0.29-0.81) while BB-AVF were more likely to fail cannulation compared to RC-AVF (adjusted OR 2.24, 95% CI 1.07-4.53).

DISCUSSION

This post-hoc analysis of a large multinational, multicentre, randomized controlled trial demonstrated that AVF failure was independently associated with female sex, lower diastolic pressure, presence of CVC and medically required use of aspirin. Potentially modifiable surgery-related factors including surgical expertise, anesthesia and AVF type were not associated with AVF failure. Factors associated with individual components of AVF failure differed. Female sex, presence of PVD and type of AVF created were associated with AVF abandonment while low diastolic blood pressure, presence of central venous catheter and non-Malaysia region of recruitment were additional risk factors for cannulation failure.

The association between female sex and higher risk of AVF failure has been reported previously\textsuperscript{12,19,20,33}, however the biological process underpinning this observation remains uncertain. While there is commonly held belief that females have smaller vessel calibre and therefore are at increased risk of AVF failure, a retrospective sonographic evaluation of vessel size in 192 patients did not find consistent differences in vascular calibre between the two sexes\textsuperscript{34}. In this study, females were twofold more likely to have their AVF created in their upper limb compared to their male counterparts. This may reflect physicians’ preference for upper arm AVF in females to avoid inadequate vessel size. Unfortunately, there was no mandatory sonographic assessment of participants’ vessels in the FAVOURED trial to further explore this hypothesis. Although female participants in the FAVOURED study exhibited
lower diastolic blood pressure, no significant interaction was observed to account for additional risk attributable to sex. Despite the increased risk of AVF failure in females, careful selection and preparation of female patients considered suitable for AVF surgery with thorough physical examination and pre-operative sonographic examination of venous access may further improve outcomes\textsuperscript{16,35}.

Earlier studies suggested that tight control of systolic, diastolic and/or mean arterial pressures pre-operatively was associated with increased odds of AVF thrombosis\textsuperscript{36,37} and early primary AVF failure\textsuperscript{38,39}. Pandey et al studied 224 patients prospectively and reported that patients with early AVF failure had lower diastolic blood pressure of 88.4 mmHg compared to 91.2 mmHg in those with AVF success\textsuperscript{39}. Similarly, a retrospective review of 1051 patients found patients with early primary failure had lower diastolic pressure of 79.7 mmHg compared to 83.1 mmHg in those with AVF success\textsuperscript{38}. In the present study, lower diastolic blood pressure and mean arterial pressure pre-surgery were associated with an increased risk of AVF failure with an AVF failure exceeding 50% at a diastolic blood pressure of 80 mmHg or lower. Higher pulse pressure, a potential measure of decreased vessel compliance, was observed to be associated with higher odds of AVF failure but this was not statistically significant. After the creation of AVF, intra-dialytic hypotension has also been associated with a higher risk of AVF thrombosis\textsuperscript{40}. Lower diastolic pressure may lead to venous stasis thereby predisposing to early AVF thrombosis and may also reflect reduced vascular compliance associated with a wider pulse pressure, both impairing vascular remodelling and maturation\textsuperscript{41}. These findings suggest that maintaining a higher perioperative diastolic blood pressure may be a modifiable factor to improve AVF outcomes. However, prospective randomized controlled studies are required to establish causality and recommend an optimal
blood pressure target taking into consideration the overall perioperative risk profile and anticipated benefits.

The finding of an increased risk of AVF failure in patients with a CVC in this study is consistent with that reported in the Dialysis Outcomes and Practice Patterns Study\textsuperscript{42-44}. This increased risk may be related to potential hemodynamic effects and central vein stenosis associated with ipsilateral catheter placement\textsuperscript{45}. In addition, CVC predispose patients to blood stream infection and hospitalization\textsuperscript{46} which could indirectly predispose to AVF failure via hypotension and the inflammatory response. However, CVC use may be a surrogate of patients referred late to a nephrology service, a known predictor of AVF failure \textsuperscript{11,44} or other unadjusted confounders.

Whilst the FAVOURED study demonstrated that neither aspirin nor fish oil use was protective against AVF failure\textsuperscript{31}, this post hoc analysis did find that patients who were required to continue on open-label aspirin for clinical indications were more likely to experience AVF failure. Although cardiovascular disease such as IHD and PVD were not associated with AVF outcomes, it is possible that open-label aspirin use identified patients with more severe cardiovascular disease that was not adequately adjusted for in multivariable logistic regression.

Another finding of the present study was that different factors were associated with individual components of AVF failure. While female sex was associated with overall poorer AVF outcomes, the presence of PVD was the predominant predictor of AVF abandonment. Participants with PVD may be at increased risk of steal syndrome or identify a population
with more diffuse atherosclerosis, which might limit intervention to promote maturation and prevent AVF abandonment. While the AVF location was not significantly associated with an increased risk of the composite outcome of AVF failure (p=0.06), it was associated with an increased risk of cannulation failure (p=0.04); Specifically, brachiobasilic AVFs were less likely to be successfully cannulated compared to radiocephalic AVFs. However, it remains unclear whether this is a statistical type 1 error given the number of comparisons and small sample size. Alternatively, the observed association may have been due to the fact that brachiobasilic vessels tend to be deeper and technically more challenging to cannulate. It is also possible that other unadjusted factors including prior history of AVF failure as a predictor of future AVF failure\textsuperscript{47,48} maybe driving this association.

Despite selection of a comprehensive list of factors that might predict AVF failure, the overall diagnostic accuracy of the complete model was modest with an AUC of 0.67. It is possible that the predictive ability of the model could be further improved by including other pre- and post-operative measures, such as pre-operative arterial and venous vessel size and adherence with vascular access surveillance and management protocols, which were not investigated in this study\textsuperscript{16,21}. Sonographic evaluation of artery and venous calibre has been associated with better selection of vessels suitable for AVF creation\textsuperscript{12,13,15,16}. Although, post-operative care, such as dedicated protocolised surveillance to detect early AVF dysfunction\textsuperscript{21}, has yielded mixed results with respect to preventing AVF failure in studies, it is possible that this may improve model prediction in the present study. While prediction models for AVF success are helpful, their accuracy is limited by the complexity of the process to establish a successful AVF. In particular, some practice-related factors of interest such as surgical and cannulation expertise and techniques are difficult to standardize and assess consistently across different studies and settings, thereby limiting the accuracy of prediction models.
Beyond having a successful AVF, there should also be consideration of alternatives to AVF such as arterio-venous graft, alternative dialysis such as peritoneal dialysis and even long-term tunnelled dialysis catheter depending on patient’s preferences, prior access history, expected life expectancy, anticipated dialysis start and course of kidney replacement.

The strengths of this study included the use of a well-characterized study population from a randomized controlled trial, ensuring standardized and accurate collection of patient and surgical variables. A systematic and methodical approach was also taken in the analysis. However, several limitations exist, including the limited number of participants and events, insufficient granularity of data (such as severity of comorbidities, location of the CVC in relation to the AVF, history of previous failed vascular access, indication of AVF abandonment or standardized pre-operative sonographic assessment of vessel size and quality), lack of standardized blood pressure assessment and data missingness that potentially introduced informative censoring bias. Furthermore, country-specific variation in practice patterns and expertise (e.g. surgical expertise measured as number of AVF creations as compared to phase of surgical training in this study or cannulation skills) were unavailable to better determine potentially modifiable predictors of AVF failure. This hypothesis is supported by the observation of lower risk of AVF failure amongst participants recruited in Malaysia compared to Australia, New Zealand and United Kingdom on univariable logistic regression which was no longer evident when adjusting for surgical factors in Model 2. Lastly, the trial population was younger with less PVD compared to the general hemodialysis population which could limit the generalizability of the result.

CONCLUSION:
Failure of newly created AVF is a major barrier to the successful establishment of hemodialysis access and occurred in almost 50% of study participants. Female sex, low diastolic blood pressure, the need for aspirin therapy and central venous catheter dependence were associated with an increased risk of AVF failure. Avoidance of peri-operative hypotension and central venous catheters at the time of AVF creation may help improve AVF outcomes and warrants further study.

DISCLOSURES
Drs Irish, Hawley, Kerr, Cass, Mori, Polkinghorne, and Mss Pascoe and Paul-Brent report having received grant support from the National Health and Medical Research Council (NHMRC) of Australia project grant, grants from Mylan EPD (at the time of funding was Abbott Products Operations AG), and grants from Amgen Australia Pty Ltd. Dr Johnson has previously received consultancy fees, research grants, speaker’s honoraria and travel sponsorships from Baxter Healthcare and Fresenius Medical Care. He has received consultancy fees from Astra Zeneca, AWAK and travel sponsorship from AMGEN. He is also the current recipient of a National Health and Medical Research Council Practitioner Fellowship. Dr Viecelli reports having received grant support from the NHMRC of Australia (Medical Postgraduate Scholarship) and the Royal Australasian College of Physicians (Jacquot National Health and Medical Research Council Medical Award for Excellence and Jacquot Research Establishment Fellowship). Dr Mori is supported by a Research Fellowship from the NHMRC of Australia (1042255). Carmel Hawley has previously received research grants from Baxter Healthcare and Fresenius Medical Care. Yeoungjee Cho has previously received research grants from Baxter Healthcare and Fresenius Medical Care and is a current recipient of a National Health and Medical Research Council Early Career Fellowship. All other authors have nothing to disclose.
FUNDING

The FAVOURED trial was funded by grants from the NHMRC of Australia Project Grant (Grant number APP458652), Amgen Australia Pty Ltd and Mylan EPD (at the time of funding was Abbott Products Operations AG). Study Medication was supplied by Mylan EPD (at the time of supply was Abbott Products Operations AG) [fish oil and placebo] and Bayer Healthcare [aspirin and placebo] free of charge.

ACKNOWLEDGEMENTS

Portions of this manuscript, "Predictors of arteriovenous fistula failure: A post-hoc analysis of the FAVOURED study" were presented as a moderated poster at the ERA-EDTA conference 2020.

The drug manufacturer and the NHMRC of Australia had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.

The authors listed on the first page of this article constitute the FAVOURED Trial Writing Committee. The authors gratefully acknowledge the contributions of all members of the FAVOURED Study Collaborative Group, dialysis nursing staff, trial co-ordinators, research staff and most especially trial participants.

The FAVOURED Study Collaborative Group comprises the Trial Steering Committee: Chen Au Peh, Elaine Beller, Alan Cass, Sharan Dogra, David Gracey, Elvie Haluszkiewicz, Carmel Hawley, Lai-Seong Hooi, Colin Hutchison, Ashley Irish, Peter Kerr, Amanda Mather, Stephen
McDonald, Chris McIntyre, Trevor Mori, Elaine Pascoe, Kevan Polkinghorne, Amanda Robertson, Johan Rosman, David Voss.

The Data and Safety Monitoring Board: Andrew Tonkin, Andrew Forbes, Adeera Levin, David C. Wheeler.

**The Investigators:** Krishna Karpe, Patricia Johnson, Martin Gallagher, Jenny Burman, Alistair Gillies, Leanne Garvey, Michael Suranyi, Belinda Yip, Grant Luxton, Debbie Pugh, Kathleen McNamara, Bruce Cooper, Cheryl Macadam, Kate Wyburn, Samantha Hand, Meg Jardine, Anne Heath, Dakshinamurthy Divi, Tammy Schmidt, Andrew Bofinger, Leanne Glancy, David Mudge, Amanda Coburn, Sree Krishna Venuthurpali, Elizabeth Coroneos, Suzi Hanna, George Kan, Vicki Hartig, Karen Katil, Meg Hockley, Peter Mount, Pascal Bisscheroux, Maree Ross-Smith, Rob McGinley, Anthony Perkins, Kevan Polkinghorne, Mechelle Seneviratne, Eugenie Pedagogos, Connie Karchimkus, Solomon Menahem, Suzanne Douglas, Vicki Levidiotis, Debra Broomfield, Jason Bennier, Paolo Ferrari, Ulrich Steinweadel, Ashley Irish, Maria Martin, Monika Chang, Sharan Dogra, Susan Pellicano, Helen Herson, Ravindran Visvanathan, Norlida Omar, Zanariah Arsat, Loke-Meng Ong, Ah-Heong Ang, Sukeri Mohamad, Najhah Md Nawi, Anita Bhajan Manocha, Norhaniza Bt Adom, Lai-Seong Hooi, Wen Jiun Liu, Mohd Rais Bin Periman, Norisham Bin Mohd Dom, Zawawi Nordin, Suhaizan Bt Mohd Rasidi, Indralingam Vaithilingam, Ramli Zaraee, Lim Soo Kun, Tiviyah Sinniah, John Schollum, Liz Berry, David Voss, Penelope Eadie, Chris McIntyre, Marie Appleby.

**The AKTN Executive Committee Members:** Neil Boudville, Alan Cass, Carmel Hawley, Meg Jardine, David Johnson, Vlado Perkovic.
The AKTN Project Management Team: Carmel Hawley, David Johnson, Alicia Morrish, Elaine Pascoe, Peta-Anne Paul-Brent, Donna Reidlinger, Liza Vergara. Elaine Beller, Sunil Badve, Anish Scaria, Stephane Heritier.

The complete list of contributing institutions is included as a supplemental appendix.

Author Contributions
YP See: Formal analysis; Methodology; Project administration; Writing - original draft; Writing - review and editing
Y Cho: Formal analysis; Supervision; Writing - original draft; Writing - review and editing
E Pascoe: Data curation; Formal analysis; Methodology; Supervision; Writing - original draft; Writing - review and editing
A Cass: Writing - review and editing
D Voss: Writing - review and editing
L-S Hooi: Writing - review and editing
L Ong: Writing - review and editing
PA Paul-Brent: Data curation; Project administration; Writing - review and editing
P Kerr: Writing - review and editing
T Mori: Writing - review and editing
C Hawley: Conceptualization; Formal analysis; Methodology; Supervision; Writing - original draft; Writing - review and editing
D Johnson: Conceptualization; Methodology; Supervision; Writing - original draft; Writing - review and editing
A Irish: Writing - review and editing
K Polkinghorne: Writing - review and editing
A Viecelli: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Writing - original draft; Writing - review and editing

Supplementary Material
Appendix: Omega 3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Group
Table S1. Cannulation Assessment Periods
Table S2. Baseline blood pressure profile according to gender
Table S3. Site of AVF created according to gender

Figure S1. Proportion of arteriovenous fistula failure (composite outcome of arteriovenous fistula abandonment, thrombosis and failure to cannulate) with change in mean arterial pressure.

Figure S2. Proportion of arteriovenous fistula failure (composite outcome of arteriovenous fistula abandonment, thrombosis and failure to cannulate) with change in systolic blood pressure.

Figure S3. Proportion of arteriovenous fistula failure (composite outcome of arteriovenous fistula abandonment, thrombosis and failure to cannulate) with change in pulse pressure.

REFERENCE

1. Polkinghorne KR, Chin GK, MacGinley RJ, Owen AR, Russell C, Talaulikar GS, Vale E, Lopez-Vargas PA. KHA-CARI Guideline: vascular access - central venous catheters, arteriovenous fistulae and arteriovenous grafts. Nephrology (Carlton): 18(11):701-705, 2013

2. Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, Kooman J, Martin-Malo A, Pedrini L, Pizzarelli F, Tattersall J, Vennegoor M, Wanner C, ter Wee P, Vanholder R. EBPG on Vascular Access. Nephrol Dial Transplant: 22 Suppl 2:ii88-117, 2007.

3. NKF-DOQI clinical practice guidelines for vascular access: 2019 Update. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis.:75 (Suppl 2):S51-164, 2019.

4. Lok CE. Fistula first initiative: advantages and pitfalls. Clin J Am Soc Nephrol.:2(5):1043-1053, 2007.
5. Malas MB, Canner JK, Hicks CW, Isibor J Arhuidese, Devin S Zarkowsky, Umar Qazi, Eric B Schneider, James H Black, Dorry L Segev, Julie A Freischlag. Trends in incident hemodialysis access and mortality. *JAMA Surg.* 150(5):441-448, 2015.

6. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. *J Am Soc Nephrol.* 7(4):523-535, 1996.

7. Al-Jaishi AA, Oliver MJ, Thomas SM, Charmaine E Lok, Joyce C Zhang, Amit X Garg, Sarah D Kosa, Robert R Quinn, Louise M Moist. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. *Am J Kidney Dis.* 63(3):464-478, 2014.

8. Allon M, Robbin ML. Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. *Kidney Int.* 62(4):1109-1124, 2002.

9. Viecelli AK, Howell M, Tong A, Armando Teixeira-Pinto, Emma O'Lone, Angela Ju, Jonathan C Craig, Lai-Seong Hooi, Timmy Lee, Charmaine E Lok, Kevan R Polkinghorne, Robert R Quinn, Tushar J Vacchharajani, Raymond Vanholder, Li Zio, Jan Tordoir, Robert Pecoits-filho, Theodore You, Pascal Kopperschmidt, Rob Smith, Ashley B Irish, Trevor A Mori, Elaine M Pascoe, David W Johnson, Carmel M Hawley. Identifying critically important vascular access outcomes in trials of haemodialysis: an international survey with patients, caregivers and health professionals. *Nephrol Dial Transplant* Aug 1, 2019. (Epub. ahead of print)

10. Lilly MP, Lynch JR, Wish JB, Edwin D Huff, Shu-Cheng Chen, Nancy C Armistead, William M McClellan. Prevalence of arteriovenous fistulas in incident hemodialysis patients: correlation with patient factors that may be associated with maturation failure. *Am J Kidney Dis.* 59(4):541-549, 2012.
11. Ravani P, Marcelli D, Malberti F. Vascular access surgery managed by renal physicians: the choice of native arteriovenous fistulas for hemodialysis. *Am J Kidney Dis.*. 40(6):1264-1276, 2002.

12. Jamil M, Usman R. Predictive parameters for successful functional maturation of native arteriovenous fistula. *J Ayub Med Coll Abbottabad.* 27(4):821-824, 2015.

13. Lockhart ME, Robbin ML, Allon M. Preoperative sonographic radial artery evaluation and correlation with subsequent radiocephalic fistula outcome. *J Ultrasound Med.* 23(2):161-168, 2004.

14. Lauvao LS, Ihnat DM, Goshima KR, Chavez L, Gruessner AC, Mills JL. Vein diameter is the major predictor of fistula maturation. *J Vasc Surg.* 49(6):1499-1504, 2009.

15. Achneck HE, Sileshi B, Li M, Partington EJ, Peterson DA, Lawson JH. Surgical aspects and biological considerations of arteriovenous fistula placement. *Semin Dial.* 23(1):25-33, 2010.

16. Allon M, Lockhart ME, Lilly RZ, MH Gallichio, CJ Young, J Narker, MH Deierhoi, ML Robbin. Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. *Kidney Int.* 60(5):2013-2020, 2001.

17. Zouaghi MK, Lammouchi MA, Hassen M, Lamia R, Madiha K, Wided S, Hela J Rania K, Rehi BH, Fatma LB, Soumaya B. Determinants of patency of arteriovenous fistula in hemodialysis patients. *Saudi J Kidney Dis Transpl.* 29(3):615-622, 2018.

18. Polkinghorne KR, McDonald SP, Marshall MR, Atkins RC, Kerr PG. Vascular access practice patterns in the New Zealand hemodialysis population. *Am J Kidney Dis.* 43(4):696-704, 2004.
19. Lazarides MK, Iatrou CE, Karanikas ID, Kaperonis NM, Petras DI, Zirogiannis PN, Dayantas JN. Factors affecting the lifespan of autologous and synthetic arteriovenous access routes for haemodialysis. *Eur J Surg.*:162(4):297-301, 1996.

20. Masengu A, Maxwell AP, Hanko JB. Investigating clinical predictors of arteriovenous fistula functional patency in a European cohort. *Clin Kidney J.* :9(1):142-147, 2016.

21. Allon M, Imrey PB, Cheung AK, Milena Radeva. Charles E Alpers, Gerald J Beck, Laura M Dember, Alik Farber, Tom Greene, Jonathan Himmelfarb, Thomas S Huber, James S Kaufman, John W Kusek, Prabir Roy-Chaudhury, Michelle L Robbin, Miguel A Varquez, Harold I Feldman, Hemodialysis Fistula Maturation Study Group. Relationships Between Clinical Processes and Arteriovenous Fistula Cannulation and Maturation: A Multicenter Prospective Cohort Study. *Am J Kidney Dis.* :71(5):677-689, 2018.

22. Aitken E, Jackson A, Kearns R, Steven M, Kinsella J, Clancy M, Macfarlane A. Effect of regional versus local anaesthesia on outcome after arteriovenous fistula creation: a randomised controlled trial. *Lancet.*:388(10049):1067-1074, 2016.

23. van der Linden J, Lameris TW, van den Meiracker AH, de Smet AA, Blankestijn PJ, van den Dorpel MA. Forearm venous distensibility predicts successful arteriovenous fistula. *Am J Kidney Dis.*:47(6):1013-1019, 2006.

24. Usta E, Elkrinawi R, Salehi-Gilani S, Sara Adili, Thorsten Sonnentag, Mark Alshcer, Ferruh Artunc, Ulrich Franke. Risk factors predicting the successful function and use of autogenous arteriovenous fistulae for hemodialysis. *Thorac Cardiovasc Surg.*:61(5):438-444, 2013.
25. Smith GE, Souroullos P, Cayton T, Harwood A, Carradice D, Chetter IC. A systematic review and meta-analysis of systemic intraoperative anticoagulation during arteriovenous access formation for dialysis. *J Vasc Access.*:17(1):1-5, 2016.

26. Regus S, Almasi-Sperling V, Rother U, Meyer A, Lang W. Surgeon experience affects outcome of forearm arteriovenous fistulae more than outcomes of upper-arm fistulae. *J Vasc Access.*:18(2):120-25, 2017.

27. Lok CE, Allon M, Moist L, Oliver MJ, Shah H, Zimmerman D. Risk equation determining unsuccessful cannulation events and failure to maturation in arteriovenous fistulas (REDUCE FTM I). *J Am Soc Nephrol.*:17(11):3204-3212, 2006.

28. Viecelli AK, O'Lone E, Sautenet B, Jonathan C Craig, Allison Tong, Eric Chemia, Lai-Seong Hooi, Timmy Lee, Charmaine Lok, Kevan R Polkinghorne, Robert R Quinn, Rushcar Vachharajani, Raymond Vanholder, Li Zuo, Ashley B Irish, Trevor A Mori, Elaine M Pascoe, David W Johnson, Carmel M Hawley. Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review. *Am J Kidney Dis.*:71(3):382-391, 2018.

29. Bylsma LC, Gage SM, Reichert H, Dahl SLM, Lawson JH. Arterio Fistulae for Haemodialysis: A Systematic Review and Meta-analysis of Efficacy and Safety Outcomes. *Eur J Vasc Endovasc Surg.*:54(4):513-522, 2017.

30. Viecelli AK, Elaine Pascoe, Polkinghorne KR, Carmel M Hawley, Peta-Ane Paul-Brent, Sunil A Badve, Alan Cass, Stephane Heritier, Peter G Kerr, Trevor A Mori, Amanda Robertson, Lai-Seong Hooi, Ashley B Irish, FAVOURED study team. The Omega-3 Fatty Acid (Fish Oil) and Aspirin in Vascular Outcomes in Renal Disease
FAVOURED study: the updated final trial protocol and rationale of post initiation trial modifications. *BMC Nephrology* :16:89, 2015.

31. Irish AB, Viecelli AK, Hawley CM, Lai Seong Hooi, Elaine M Pascoe, Peta-Anne Paul-Brent, Sunil V Badve, Trevor A Mori, Alan Cass, Peter G Kerr, David Voss, Loke Meng Ong, Kevan R Pollinghorne, FAVOURED Study Group. Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial. *JAMA Intern Med.* :177(2):184-193, 2017.

32. Yan Y, Ye D, Yang L, Wen Ye, Danda Zhan, Li Zhang, Jun Xiao, Yan Z, Qinkai C. A meta-analysis of the association between diabetic patients and AVF failure in dialysis. *Ren Fail.* :40(1):379-383, 2018.

33. Lee T, Qian J, Thamer M, Allon M. Gender Disparities in Vascular Access Surgical Outcomes in Elderly Hemodialysis Patients. *Am J Nephrol.* :49(1):11-19, 2019.

34. Caplin N, Sedlacek M, Teodorescu V, Falk A, Uribarri J. Venous access: women are equal. *Am J Kidney Dis.* :41(2):429-432, 2003.

35. Okamuro L, Gray K, Korn A, Parrish A, Kaji A, Erin C Howel, Bowens N, Chirstian de Virgilio. Careful Patient Selection Achieves High Radiocephalic Arteriovenous Fistula Patency in Diabetic and Female Patients. *Ann Vasc Surg.* :57:16-21, 2019.

36. Irvinn J, Oldman N, Sedgwick P, Chemla E. Do blood pressure levels and other patient characteristics influence native fistula patency? *Semin Dial.* :27(3):E27-31, 2014.

37. Culp K, Flanigan M, Taylor L, Rothstein M. Vascular access thrombosis in new hemodialysis patients. *Am J Kidney Dis.* :26(2):341-346, 1995.

38. Yan Y, Su X, Zheng J, Zhang L, Yang L, Jiang Q, Chen L. Association of Preoperative Mean Arterial Pressure With the Primary Failure of Brescia-Cimino
Arteriovenous Fistula Within the First 7 Days Following Surgery in Hemodialysis Patients. *Ther Apher Dial.*:22(5):539-543, 2018.

39. Pandey S, Kumar M, Agrawal M, Singh M, Aggarwal A, Garg G, Agarwal S, Sankhwar S. The effects of preoperative blood pressure on early failure rate of distal arteriovenous fistulas for hemodialysis access. *Hemodial Int.*:23(3):314-318, 2019.

40. Chang TI, Paik J, Greene T, Desai M, Bech F, Cheung AK, Chertow GM. Intradialytic hypotension and vascular access thrombosis. *J Am Soc Nephrol.*:22(8):1526-1533, 2011.

41. Gavish B, Izzo JL, Jr. Arterial Stiffness: Going a Step Beyond. *Am J Hypertens.*:29(11):1223-1233, 2016.

42. Rayner HC, Pisoni RL, Gillespie BW, Goodkin DA, Akiba T, Akizawa T, Saito A, Young EW, Port FK, Dialysis Outcomes and Practice Patterns Study. Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study. *Kidney Int.*:63(1):323-330, 2003.

43. Rayner HC, Besarab A, Brown WW, Disney A, Saito A, Pisoni RL. Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. *Am J Kidney Dis.*:44(5 Suppl 2):22-26, 2004.

44. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ. Vascular access use in Europe and the United States: results from the DOPPS. *Kidney Int.*:61(1):305-316, 2002.

45. Ozpak B, Yilmaz Y. Arteriovenous fistulas ipsilateral to internal jugular catheters for hemodialysis have decreased patency rates. *Vascular*:1708538118811483, 2018.
46. Ng LJ, Chen F, Pisoni RL, Mahesh Krishnan, Donna Mapes, Marcia Keen, Brian D Bradbury. Hospitalization risks related to vascular access type among incident US hemodialysis patients. *Nephrol Dial Transplant.:* 26(11):3659-3666, 2011.

47. Timmy Lee, Ahsan U, Allon M, Paul S, Mahmoud EK, Rino M, Prabir RC. Decreased cumulative access survival in arteriovenous fistulas requiring interventions to promote maturation. *Clin J Am Soc Nephrology:* 6(3):575-81, 2011.

48. Kathleen D, Gibson MD, Daniel L Gillen BS, Michael T Caps, Ted R Kohler, Donald J Sherrald, Catherine O Stehman Breen. Vascular access survival and incidence of revisions: A comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System Dialysis Morbidity and Mortality study. *J Vasc Surg:* 34(4): 694-700, 2001.

49. K Woo, J Ulloa, M Allon, Christopher G Carsten, Eric S Chemla, Mitchell L Henry, Thomas S Huber, Jeffery H Lawson, Charmaine E Lok, Eric K Peden, Larry Scher, Anton Sidawy, Melinda MG, David Cull. Establishing patient-specific criteria for selecting optimal upper extremity vascular access. *J Vasc Surg:* 65(4): 1089-1103, 2017.
### Table 1. Baseline characteristics of the study population.

| Parameter | All participants (n=536) | Patients without AVF failure (n=283) | Patients with AVF failure (n=253) | p-value |
|-----------|--------------------------|-------------------------------------|-----------------------------------|---------|
| Female, n (%) | 194 (36) | 89 (32) | 105 (42) | 0.02 |
| Age (years) | 55.0 ± 14.4 | 53.6 ± 14.3 | 56.5 ± 14.4 | 0.02 |
| Ethnicity, n (%) | 259 (54) | 21 (4) | 9 (3) | 0.25 |
| - Caucasoid | 289 (54) | 89 (32) | 105 (42) | 0.02 |
| - Asians | 169 (32) | 101 (36) | 68 (27) |
| - Aboriginal and Torres Strait Islander | 21 (4) | 9 (3) | 12 (5) |
| - Maori and Pacific Islander | 38 (7) | 20 (7) | 18 (7) |
| - Others | 19 (4) | 10 (4) | 9 (4) |
| Region of recruitment, n (%) | 392 (73) | 193 (68) | 199 (79) | 0.01 |
| - Australia/NZ/UK | 144 (27) | 90 (32) | 54 (21) |
| Cause of ESKD, n (%) | 202 (38) | 72 (13) | 40 (8) | 0.25 |
| - Diabetes Mellitus | 140 (26) | 53 (10) | 21 (4) |
| - Glomerulonephritis | 40 (8) | 26 (5) | 12 (5) |
| - Hypertension | 21 (4) | 17 (3) | 11 (3) |
| - Polycystic | 125 (23) | 79 (15) | 41 (16) | 0.37 |
| - Reflux | 23 (4) | 12 (4) | 6 (2) |
| - Others | 79 (15) | 38 (13) | 20 (7) | 0.52 |
| BMI | 27.2 (23.4-32.0) | 27.1 (23.9-31.7) | 27.5 (23.0-32.5) | 0.83 |
| Comorbidity, n (%) | 475 (89) | 259 (92) | 216 (85) | 0.03 |
| - Hypertension | 243 (45) | 132 (47) | 111 (44) | 0.52 |
| - DM | 53 (10) | 24 (9) | 29 (12) | 0.25 |
| - CCF | 21 (4) | 12 (4) | 9 (4) | 0.68 |
| - PVD | 23 (4) | 8 (3) | 15 (6) | 0.08 |
| - CVD | 17 (3) | 11 (4) | 6 (2) | 0.32 |
| - Composite of IHD, CVD and PVD | 79 (15) | 38 (13) | 41 (16) | 0.37 |
| Baseline blood pressure (mmHg) | 146.1 ± 23.0 | 147.2 ± 21.9 | 144.9 ± 24.2 | 0.25 |
| - SBP | 81.4 ± 13.4 | 83.1 ± 12.9 | 79.5 ± 13.6 | <0.01 |
| - DBP | 103.0 ± 14.4 | 104.5 ± 13.6 | 101.3 ± 15.0 | 0.01 |
| - MAP | 64.1 ± 20.0 | 64.1 ± 19.6 | 65.4 ± 20.5 | 0.45 |
| HbA1c (%) * | 6.2 ± 1.4 | 6.3 ± 1.5 | 6.2 ± 1.3 | 0.25 |
| LDL-C (mmol/L) * | 2.4 (1.8-3.1) | 2.6 (1.9-3.3) | 2.3 (1.7-3.1) | 0.07 |
| Smoking, n (%) | 264 (49) | 137 (48) | 127 (50) | 0.68 |
| - never | 272 (51) | 146 (52) | 126 (50) |
| - current or previous | 268 (50) | 139 (49) | 129 (51) | 0.63 |
| Presence of central venous catheter, n (%) | 218 (41) | 107 (38) | 111 (44) | 0.15 |
| Serum Albumin (g/L) | 36 (32-40) | 37 (33-41) | 36 (32-40) | 0.22 |
| PTH (pmol/L) * | 28 (16.1-45.3) | 30.2 (16.6-50.8) | 26.6 (15.2-40.8) | 0.05 |
| INR* | 1(1.0-1.1) | 1(0.9-1.1) | 1(1.1-1.1) | 0.58 |
| APTT* | 30.1(27-34) | 31(27.7-35) | 30 (27-34) | 0.09 |
|                     | 108.2 ±18.6 | 106.8 ±17.7 | 109.7 ±19.5 | 0.08 |
|---------------------|-------------|-------------|-------------|-----|
| **Hemoglobin (g/L)** |             |             |             |     |
| **Platelets**       | 233 (191-288) | 233(193-289) | 233(191-287) | 0.83 |
| Medications, n (%)  |             |             |             |     |
| - Statin            | 275 (51)    | 148 (52)    | 127 (50)    | 0.63 |
| - ESA,              | 253 (47)    | 139 (49)    | 114 (45)    | 0.35 |
| - Beta-blockers     | 247 (46)    | 135 (48)    | 112 (44)    | 0.43 |
| - ACE-I /ARB        | 224 (42)    | 117 (41)    | 107 (42)    | 0.82 |
| - CCB               | 299 (56)    | 167 (59)    | 132 (52)    | 0.11 |
| Surgeons, n (%)     |             |             |             | 0.43 |
| -Consultants        | 419 (78)    | 225 (80)    | 194 (77)    |     |
| -Registrars/Residents| 117 (22)   | 58 (21)     | 59 (23)     |     |
| Type of anesthesia, n (%) |        |             |             | 0.08 |
| -Local              | 211 (40)    | 122 (43)    | 89 (36)     |     |
| -Regional/General anesthesia | 322 (60)    | 161 (57)    | 161 (64)    |     |
| AVF created, n (%)  |             |             |             | 0.08 |
| - Radiocephalic     | 312 (58)    | 168 (59)    | 144 (57)    |     |
| - Brachiocephalic   | 180 (34)    | 99 (35)     | 81 (32)     |     |
| - Brachiobasilic    | 37 (7)      | 12 (4)      | 25 (10)     |     |
| - Others            | 7 (1)       | 4 (1)       | 3 (1)       |     |
| Intra-operative heparin, n (%) | 352 (66)    | 184 (65)    | 168 (67)    | 0.73 |
| Randomization to aspirin, n (%) | 194 (36)    | 107 (38)    | 87 (34)     | 0.04 |
| - Randomized to placebo | 194 (36)   | 111 (39)    | 83 (33)     |     |
| - Randomized to aspirin | 148 (28)    | 65 (23)     | 83 (33)     |     |
| Randomization to Fish Oil, n (%) | 270 (50)    | 142 (50)    | 128 (51)    | 0.92 |

# Continuous variables are presented in means (± standard deviation) if normally distributed and median (interquartile range) if non-normal distribution.

^ AVF failure is defined as composite of AVF thrombosis and/or failure to cannulate and/or abandonment of AVF within 12 months of AVF creation

* Variables with more than 5% missing data

Abbreviations: NZ- New Zealand; UK- United Kingdom; ESKD – end-stage kidney disease; BMI – body mass index; DM- diabetes mellitus; IHD- ischemic heart disease; CCF - congestive cardiac failure; CVD - cerebrovascular disease; GN – glomerulonephritis; SBP- systolic blood pressure; DBP -diastolic blood pressure; MAP – mean arterial pressure; PP – pulse pressure; KRT – Kidney replacement therapy; LDL-C – low-density lipoprotein; PTH - parathyroid hormone; PVD - peripheral vascular disease; INR- international normalized ratio; APTT- activated partial thromboplastin time; ESA – erythropoietin stimulating agent; ACE-I/ARB- angiotensin converting enzyme inhibitor/ angiotensin receptor blocker; CCB- calcium channel blocker; AVF – arteriovenous fistula

Independent student t-test and Mann-Whitney U test performed for continuous variable when appropriate. Chi-squared test and Fischer-exact test performed for categorical variables when appropriate.
### Table 2. Logistic Regression of patient and surgical factors associated with arterio-venous fistula failure.

| Parameter                   | Univariable Odds Ratio (95% CI) | P-value | Model 1^ Odds Ratio (95% CI) | P-value | Model 2* Odds Ratio (95% CI) | P-value |
|-----------------------------|---------------------------------|---------|-----------------------------|---------|-----------------------------|---------|
| Female                      | 1.54 (1.09-2.20)                | 0.02    | 1.60 (1.10-2.32)            | 0.01    | 1.79 (1.20-2.68)            | <0.01   |
| Age (per 10 years)          | 1.15 (1.02-1.29)                | 0.02    | 1.06 (0.92-1.21)            | 0.42    | 1.06 (0.92-1.22)            | 0.41    |
| Ethnicity                   |                                 |         |                             |         |                             |         |
| - Caucasoid                 | Ref                             | 0.25    | -                           | -       | -                           | -       |
| - Asians                    | 0.66 (0.45-0.97)                |         |                             | -       | -                           | -       |
| - Aboriginal and Torres Strait Islander | 1.31 (0.53-3.19) |         |                             | -       | -                           | -       |
| - Maori and Pacific Islander | 0.88 (0.45-1.74)               |         |                             | -       | -                           | -       |
| - Others                    | 0.88 (0.35-2.23)                |         |                             | -       | -                           | -       |
| Region ^                    |                                 |         |                             |         |                             |         |
| - Australia/NZ/UK           | Ref                             | 0.01    | Ref                         | 0.03    | Ref                         | 0.20    |
| - Malaysia                  | 0.58 (0.39-0.86)                |         | 0.60 (0.38-0.95)            |         | 0.66 (0.34-1.25)            |         |
| Cause of ESKD               |                                 |         |                             |         |                             |         |
| - DM                        | Ref                             | 0.90    | -                           | -       | -                           | -       |
| - GN                        | 0.85 (0.49-1.46)                |         |                             | -       | -                           | -       |
| - Hypertension              | 0.82 (0.48-1.42)                |         |                             | -       | -                           | -       |
| - APKD                      | 0.78 (0.40-1.56)                |         |                             | -       | -                           | -       |
| - Reflux                    | 0.91 (0.40-2.06)                |         |                             | -       | -                           | -       |
| - Others                    | 1.08 (0.69-1.68)                |         |                             | -       | -                           | -       |
| BMI                         | 1.01 (0.99-1.04)                | 0.33    | -                           | -       | -                           | -       |
| Hypertension                | 0.54 (0.31-0.93)                | 0.03    | -                           | -       | -                           | -       |
| DM                          | 0.89 (0.64-1.26)                | 0.52    | 0.81 (0.55-1.20)            | 0.29    | 0.85 (0.57-1.27)            | 0.42    |
| IHD                         | 1.40 (0.79-2.47)                | 0.25    | -                           | -       | -                           | -       |
| PVD                         | 2.17 (0.90-5.20)                | 0.08    | 1.78 (0.70-4.53)            | 0.23    | 1.87 (0.74-4.78)            | 0.19    |
| CCF                         | 0.83 (0.35-2.01)                | 0.68    | -                           | -       | -                           | -       |
| Cerebrovascular disease     | 0.60 (0.22-1.65)                | 0.32    | -                           | -       | -                           | -       |
| Composite of IHD, CVD and PVD | 1.25 (0.77-2.01) | 0.37    | -                           | -       | -                           | -       |
| SBP (per 10 mmHg)           | 0.96 (0.89-1.03)                | 0.25    | -                           | -       | -                           | -       |
| DBP (per 10 mmHg)           | 0.81 (0.71-0.93)                | <0.01   | 0.84 (0.73-0.97)            | 0.02    | 0.85 (0.74-0.99)            | 0.04    |
| MAP (per 10 mmHg)           | 0.85 (0.76-0.96)                | 0.01    | -                           | -       | -                           | -       |
| Variable                                    | Value 1 | Value 2 | Value 3 | Value 4 | Value 5 |
|---------------------------------------------|---------|---------|---------|---------|---------|
| PP (per 10 mmHg)                            | 1.03 (0.95-1.13) | 0.45 | - | - | - |
| HbA1c (%)                                   | 0.93 (0.82-1.05) | 0.25 | - | - | - |
| LDL-C (mmol/L)                              | 0.86 (0.72-1.01) | 0.07 | - | - | - |
| Smoking                                    | Ref | 0.68 | - | - | - |
| - Never smoker                              | Ref | 0.66-1.31 | - | - | - |
| - Current or former smoking                 | 0.92 (0.65-1.29) | 0.63 | - | - | - |
| Presence of previous history of kidney      | 1.29 (0.91-1.82) | 0.15 | 1.53 (1.05-2.23) | 0.03 | 1.49 (1.02-2.20) | 0.04 |
| replacement therapy                         | Serum Albumin (g/L) | 0.98 (0.96-1.01) | 0.22 | - | - | - |
| PTH (pmol/L)                                | 0.99 (0.99-0.99) | 0.03 | - | - | - | - |
| INR#                                       | 1.13 (0.57-2.26) | 0.73 | - | - | - | - |
| APTT#                                      | 0.99 (0.98-1.01) | 0.40 | - | - | - | - |
| Hemoglobin (g/L)                            | 1.01 (1.00-1.02) | 0.08 | 1.01 (0.99-1.02) | 0.27 | 1.01 (0.99-1.02) | 0.30 |
| Platelets                                  | 1.00 (0.99-1.00) | 0.85 | - | - | - | - |
| Statin use                                  | 0.92 (0.65-1.29) | 0.63 | - | - | - | - |
| ESA use                                    | 0.85 (0.60-1.19) | 0.35 | - | - | - | - |
| Beta-blocker use                            | 0.87 (0.62-1.22) | 0.47 | - | - | - | - |
| ACE-I/ARB use                               | 1.04 (0.74-1.47) | 0.82 | - | - | - | - |
| CCB use                                    | 0.76 (0.54-1.07) | 0.11 | 0.86 (0.60-1.25) | 0.44 | 0.84 (0.58-1.22) | 0.35 |
| Surgeons                                   | Ref | 0.91 (0.59-1.40) | 0.66 | - | - | - |
| - Trainees                                  | Ref | 0.56-1.28 | - | - | - | - |
| - Consultant                               | 0.85 (0.56-1.28) | 0.43 | - | - | - | - |
| Anesthesia                                 | Ref | 0.93 (0.54-1.63) | 0.81 | - | - | - |
| - Regional/General anesthesia               | Ref | 0.51-1.04 | 0.08 | - | - | - |
| - Local                                    | 0.73 (0.51-1.04) | 0.08 | - | - | - | - |
| Intra-operative heparin                     | 1.07 (0.74-1.52) | 0.73 | - | - | - | - |
| AVF type                                   | Ref | 0.93 (0.54-1.63) | 0.81 | - | - | - |
| - Radiocephalic                            | Ref | 0.51-1.04 | 0.08 | - | - | - |
| - Brachiocephalic                          | 0.76 (0.50-1.16) | 0.73 | - | - | - | - |
| - Bachiobasilic                            | 2.24 (1.10-5.05) | 0.84 (0.58-1.22) | 0.35 | - | - | - |
| - Others                                   | 2.43 (1.18-5.01) | 0.88 (0.19-3.97) | 0.06 | - | - | - |
| Randomization to aspirin | Ref   | 0.04 | Ref   | 0.05 | Ref   | 0.03 |
|--------------------------|-------|------|-------|------|-------|------|
| - Randomized to placebo  | 0.92 (0.62-1.37) | 0.89 (0.59-1.35) | 0.85 (0.55-1.29) |
| - Randomized to aspirin  | 1.57 (1.02-2.42) | 1.59 (1.00-2.53) | 1.60 (1.00-2.56) |
| - Open label aspirin     |       |      |       |      |       |      |
| Randomization to fish oil use | 1.02 (0.72-1.43) | 0.92 | 1.05 (0.73-1.49) | 0.80 | 1.09 (0.76-1.56) | 0.64 |

^ Model 1: Multivariable logistic regression using patient factors with p<0.2 on univariable logistic analysis and less than 5% missing data inclusive of diabetes mellitus, randomization to aspirin and fish oil forced in, patient factors included are female, age, diastolic blood pressure, region, presence of peripheral vascular disease, presence of central venous catheter, use of calcium channel blocker and hemoglobin levels.

* Model 2: Multivariable logistic regression using Model 1 with addition of surgical related factors such as surgeons, type of anesthesia use and type of AVF created.

^ Australia, New Zealand, United Kingdom region of recruitment was grouped when compared to Malaysian region of recruitment in this analysis.

# Variables with more than 5% missing data

Single imputation for missing values of individual outcome components was performed and described in detail in the primary outcome analysis 31

Abbreviations: NZ- New Zealand; UK- United Kingdom; ESKD – end-stage kidney disease; BMI – body mass index; DM- diabetes mellitus; IHD- ischemic heart disease; CCF- congestive cardiac failure; PVD- peripheral vascular disease; CVD- cerebrovascular disease; GN – glomerulonephritis; SBP- systolic blood pressure; DBP-diastolic blood pressure; MAP- mean arterial pressure; PP – pulse pressure; LDL-C – low-density lipoprotein; PTH- parathyroid hormone; INR- international normalized ratio; APTT- activated partial thromboplastin time; ESA – erythropoietin stimulating agent; ACE-I/ARB- angiotensin converting enzyme inhibitor and receptor blocker; CCB- calcium channel blocker; AVF – arteriovenous fistula
Table 3 Multivariable logistic regression analysis of patient and surgical factors for individual outcome components including AVF abandonment, thrombosis and cannulation failure at 12 months.

| Parameter                                      | Abandonment       | p-value | Thrombosis      | p-value | Failure to Cannulate | p-value |
|------------------------------------------------|-------------------|---------|------------------|---------|----------------------|---------|
| Participants with event                        | 121               | 0.109   | 212              |         |                      |         |
| Female sex                                     | 2.02 (1.27-3.20)  | <0.01   | 1.16 (0.72-1.89) | 0.54    | 1.74 (1.16-2.61)     | 0.01    |
| Age (per 10 years)                             | 1.01 (0.86-1.19)  | 0.89    | 0.92 (0.77-1.08) | 0.30    | 1.12 (0.97-1.29)     | 0.12    |
| Diastolic pressure (per 10 mmHg)               | 0.91 (0.76-1.08)  | 0.27    | 0.90 (0.75-1.07) | 0.23    | 0.80 (0.68-0.93)     | 0.01    |
| Region ^                                       |                   |         |                  |         |                      |         |
| - Australia/NZ/UK                              | Ref               | 1.18    | Ref              | 1.30    | Ref                  | 0.50    |
| - Malaysia                                     | 1.18 (0.56-2.47)  | 0.66    | 1.30 (0.57-2.97) | 0.54    | 0.50 (0.26-0.98)     | 0.04    |
| Diabetes mellitus                              | 0.87 (0.54-1.39)  | 0.55    | 0.70 (0.43-1.14) | 0.15    | 0.92 (0.61-1.38)     | 0.69    |
| Presence of PVD                                | 3.24 (1.13-7.98)  | 0.01    | 2.46 (0.95-6.35) | 0.06    | 0.92 (0.37-2.27)     | 0.85    |
| Presence of central venous catheter            | 1.03 (0.65-1.61)  | 0.91    | 0.77 (0.48-1.24) | 0.27    | 1.66 (1.11-2.46)     | 0.01    |
| Use of CCB                                     | 0.91 (0.58-1.42)  | 0.67    | 0.84 (0.53-1.32) | 0.45    | 0.88 (0.60-1.29)     | 0.51    |
| Hemoglobin                                     | 1.00 (0.99-1.01)  | 0.98    | 1.00 (0.99-1.02) | 0.58    | 1.00 (0.99-1.01)     | 0.48    |
| Randomization to aspirin                       |                   |         |                  |         |                      |         |
| - Randomized to placebo                        | Ref               | 0.16    | Ref.99 (0.58-1.68)| 0.26    | Ref                  | 0.44    |
| - Randomized to aspirin                        | 0.71 (0.42-1.18)  | 0.16    | 1.50 (0.86-2.63) | 0.26    | 0.93 (0.60-1.43)     | 0.44    |
| - Open label aspirin                           | 1.19 (0.70-2.02)  | 0.16    | 1.50 (0.86-2.63) | 0.26    | 0.93 (0.60-1.43)     | 0.44    |
| Randomization to fish oil use                  | 1.00 (0.65-1.52)  | 1.00    | 0.86 (0.56-1.33) | 0.50    | 1.13 (0.78-1.63)     | 0.53    |
| AVF type                                       |                   |         |                  |         |                      |         |
| - Brachiophalic                                | 0.48 (0.29-0.81)  | 0.05    | Ref              | 0.23    | Ref                  | 0.04    |
| - Brachiobasilic                               | 0.95 (0.41-2.19)  | 0.54    | Ref              | 0.23    | Ref                  | 0.04    |
| - Others                                       | 1.20 (0.20-7.15)  | 0.54    | Ref              | 0.23    | Ref                  | 0.04    |
| Surgeons                                       |                   |         |                  |         |                      |         |
| - Registrar/Residents                           | 0.85 (0.52-1.41)  | 0.54    | 0.65 (0.40-1.08) | 0.10    | 1.08 (0.69-1.69)     | 0.72    |
| Anesthesia                                     |                   |         |                  |         |                      |         |
| - Regional/General anesthesia                  | Ref               | 1.30    | Ref              | 0.42    | Ref                  | 0.80    |
| - Local                                        | 1.30 (0.69-2.45)  | 0.42    | 0.78 (0.39-1.55) | 0.48    | 1.08 (0.62-1.88)     | 0.80    |

Single imputation for missing values of individual outcome components was performed and described in detail in the primary outcome analysis. ^ Australia, New Zealand, United Kingdom region of recruitment was grouped when compared to Malaysian region of recruitment in this analysis.
Abbreviations: NZ- New Zealand; UK- United Kingdom; PVD – peripheral vascular disease; CCB – calcium channel blocker; RC- radiocephalic; BC-brachiocephalic; BB-Brachiobasilic; AVF – arteriovenous fistula
Figure 1. Proportion of arteriovenous fistula failure (composite outcome of arteriovenous fistula abandonment, thrombosis and failure to cannulate) with change in diastolic blood pressure.

The light grey line reflects an almost inverse linear relationship between diastolic blood pressure and proportion of AVF failure on univariable logistic regression and the dashed grey line represent the 95% confidence interval at each diastolic blood pressure level. The black line shows a similar relationship between diastolic blood pressure and proportion of AVF failure on multivariable analysis adjusted for female sex, age, region of recruitment, presence of diabetes, presence of peripheral vascular disease, presence of central venous catheter, use of calcium channel blockers, haemoglobin levels, randomization to aspirin, randomization to fish oil, type of AVF created, surgical expertise and type of anesthesia use added and the dotted black line representing the 95% confidence interval.